Exploring the Intersection of ADHD, Gender Roles, and Race-Based Trauma in Financial Decision-Making

Asper associate professor and The Associates Fellow in Finance, Chi Liao, is delving into the intersection of social phenomena and individual financial decision-making. Through her research, she aims to shed light on how factors such as ADHD, gender roles, and race-based trauma impact financial outcomes.

Liao’s work on ADHD and financial outcomes spans from childhood to retirement age, highlighting the long-lasting effects of neurodivergence on financial decision-making. She also explores the relationship between race-based trauma and financial decisions, uncovering disparities in stock market participation, home ownership, and retirement savings among different racial groups.

By analyzing data and identifying gaps in the literature, Liao seeks to challenge traditional finance assumptions and offer a more nuanced understanding of how our personal experiences and societal structures influence our financial behaviors. Her research not only provides valuable insights for academics but also offers practical implications for policymakers and practitioners in the finance industry.

Through her dedication to asking better questions and uncovering hidden patterns in financial data, Chi Liao is paving the way for a more inclusive and equitable financial landscape.

G1 Therapeutics to Host Webcast and Conference Call for First Quarter 2024 Update

G1 Therapeutics, a leading oncology company, is set to host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024. The event is scheduled for Wednesday, May 1, 2024, at 8:30 a.m. ET.

To participate in the event, interested individuals can register online to receive a dial-in number and unique PIN for access to the live conference call. While not mandatory, it is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will also be available on the Events & Presentations page of the company’s website.

G1 Therapeutics is known for its commitment to developing next-generation therapies to improve the lives of cancer patients. The company’s first commercial product, COSELA® (trilaciclib), is already making a difference in the field of oncology. Additionally, G1 Therapeutics is actively evaluating therapies in combination with cytotoxic and immunotherapy treatments for triple-negative breast cancer and extensive stage small cell lung cancer.

For more information about G1 Therapeutics and its innovative approach to cancer treatment, visit their website at www.g1therapeutics.com. You can also follow the company on social media platforms like X (formerly known as Twitter) and LinkedIn.

G1 Therapeutics is dedicated to providing groundbreaking advancements in cancer care, and the upcoming webcast and conference call will offer valuable insights into the company’s progress and future plans. Don’t miss this opportunity to learn more about the cutting-edge work being done at G1 Therapeutics.

Financial Results and Business Updates from Windtree Therapeutics, Inc. for the Fourth Quarter and Fiscal Year Ended December 31, 2023

Windtree Therapeutics, a biotechnology company focused on innovative therapies for critical conditions, has reported its financial results for the fourth quarter and fiscal year ended December 31, 2023. The company’s CEO, Craig Fraser, highlighted the productive period with advancements in clinical programs, acquisitions, and partnerships.

One of the key updates from Windtree is the acquisition of a novel oncology preclinical atypical protein kinase C iota inhibitor platform from Varian Biopharmaceuticals. This acquisition is part of the company’s portfolio optimization strategy and marks a potentially transformative step for Windtree. Additionally, the company plans to read out data from ongoing Phase 2 istaroxime trials in cardiogenic shock and support a Phase 3 program in acute heart failure.

Dr. Steve Simonson, Chief Medical Officer of Windtree, discussed the progress made by the R&D and clinical team, including advancements in the istaroxime program and the integration of the newly acquired aPKCi inhibitor into the preclinical portfolio. The company plans to focus on developing a comprehensive development plan for the aPKCi inhibitor platform, targeting malignancies with unmet needs.

In terms of financial results, Windtree reported an operating loss of $5.0 million for the fourth quarter of 2023, compared to $10.8 million in the same period in 2022. The company’s net loss for the quarter was $5.2 million. For the full year 2023, Windtree reported an operating loss of $20.6 million and a net loss of $20.3 million.

As of December 31, 2023, Windtree had cash and cash equivalents of $4.3 million and current liabilities of $4.0 million. The company completed a $1.5 million convertible note bridge financing in April 2024, providing resources to fund operations through April 2024.

Overall, Windtree Therapeutics continues to make significant strides in advancing its pipeline of innovative therapies and strengthening its position in the biotechnology industry. With key acquisitions, partnerships, and clinical advancements, the company is poised for continued growth and success in the future.

QuidelOrtho Corporation to Report First Quarter 2024 Financial Results on May 8, 2024

QuidelOrtho Corporation to Report First Quarter 2024 Financial Results

SAN DIEGO, April 17, 2024– QuidelOrtho Corporation (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, announced today that it will be reporting its financial results for the first quarter ended March 31, 2024. The report will be released after the market closes on Wednesday, May 8, 2024.

Following the release of the financial results, QuidelOrtho will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the company’s website at https://ir.quidelortho.com/. Presentation materials will also be available on the website at the time of the call. For those unable to access the webcast, a phone option is available by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 295379.

A replay of the conference call will be available on the “Investor Relations” page of the company’s website under the “Events & Presentations” section.

QuidelOrtho Corporation is a world leader in in vitro diagnostics, offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company aims to provide fast, accurate, and reliable diagnostics to patients, clinicians, and health officials worldwide.

For more information, visit www.quidelortho.com.

Source: QuidelOrtho Corporation

Contacts:
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417178380/en/

This news story highlights the upcoming financial report of QuidelOrtho Corporation and provides details on how interested parties can access the conference call to discuss the results. It also gives an overview of the company’s focus on providing innovative diagnostic solutions globally.

Propel Holdings Inc. to Report Q1 2024 Financial Results and Host Conference Call

Propel Holdings Inc. to Report Q1 2024 Financial Results

TORONTO, April 17, 2024 /CNW/ – Propel Holdings Inc. (“Propel”) (TSX: PRL), a leading fintech company focused on providing access to credit for underserved consumers, has announced that it will be releasing its financial results for the first quarter ending March 31, 2024. The report will be made public after the market closes on Wednesday, May 8, 2024.

Investors and stakeholders can look forward to a conference call and webcast featuring presentations by Clive Kinross, Chief Executive Officer, and Sheldon Saidakovsky, Chief Financial Officer. This event is scheduled to take place before the market opens on Thursday, May 9, 2024.

The conference call details are as follows:
– Date: Thursday, May 9, 2024
– Time: 8:30 a.m. EDT
– Toll-free North America: 1-888-664-6383
– Local Toronto: 1-416-764-8650
– Webcast: Click here
– Replay: 1-888-390-0541 or 1-416-764-8677 (PIN: 045046 #)

Propel Holdings is known for its innovative approach to financial services, with brands like Fora Credit, CreditFresh, and MoneyKey offering credit solutions to consumers who may not have access to traditional banking services. Through their AI-driven platform, Propel is able to evaluate customers in a more comprehensive manner, leading to better products and an expanded credit market.

To date, Propel has helped consumers access over one million loans and lines of credit, totaling over one billion dollars in credit. The company’s mission is to revolutionize the way customers, partners, and investors achieve success together.

For more information about Propel Holdings Inc. and its services, visit www.propelholdings.com.

SOURCE Propel Holdings Inc.

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/17/c2428.html